9th October 2023
AACR OVARIAN CANCER CONFERENCE PRESENTATION
• Data from preclinical studies in ovarian cancer presented at premier international conference in
Boston, USA.
• Results indicate that Amplia’s proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care in models of chemotherapy-resistant high-grade serous ovarian cancer
• Data from these studies support clinical study of narmafotinib in ovarian cancer – with plans now commencing with leading international cancer specialists
I’m guessing it is something to do with this conference ...
.
- Forums
- ASX - By Stock
- Ann: Pause in Trading
9th October 2023 AACR OVARIAN CANCER CONFERENCE PRESENTATION •...
-
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATX (ASX) to my watchlist
|
|||||
Last
6.3¢ |
Change
0.002(3.28%) |
Mkt cap ! $17.11M |
Open | High | Low | Value | Volume |
6.2¢ | 6.5¢ | 6.1¢ | $49.07K | 778.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1994 | 6.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.3¢ | 7737 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1994 | 0.062 |
1 | 41600 | 0.060 |
3 | 103326 | 0.059 |
1 | 85991 | 0.058 |
2 | 192105 | 0.057 |
Price($) | Vol. | No. |
---|---|---|
0.063 | 7737 | 1 |
0.064 | 121853 | 3 |
0.065 | 153154 | 4 |
0.070 | 6009 | 1 |
0.074 | 73026 | 1 |
Last trade - 12.11pm 03/07/2024 (20 minute delay) ? |
Featured News
ATX (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online